Press Releases and Announcements:
| August 17, 2011 |
Altor BioScience Awarded SBIR Phase I Grant by NCI for Research on its Novel IL-15 Super Agonist for Bladder Cancer |
| June 28, 2011 |
Florida Biologix Announces Manufacturing Agreement with Altor BioScience |
| May 23, 2011 |
Altor BioScience Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI to Complete a Second Phase 2 ALI/ARDS Clinical Trial for its Antibody-based Tissue Factor Antagonist, ALT-836 |
| February 16, 2011 |
Altor BioScience Awarded SBIR Phase I Grant by NIAID for HIV Research |
| January 24, 2011 |
Cancer play Altor stays majority-owned by individuals to pursue SBIRs Less VC, more SBIR |
| January 19, 2011 |
Altor BioScience Raises $10.3M Series D For Cancer Clinical Trials |
| November 3, 2010 |
S. Fla. biotechs get federal financial boost |
| September 25, 2009 |
Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801 |
| October 22, 2008 |
Altor BioScience is Awarded Grant from the Bill & Melinda Gates Foundation |
| September 10, 2008 |
Altor BioScience Licenses T-cell Receptors Targeting HIV and Hepatitis C from Massachusetts General Hospital |
| February 12, 2008 |
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech |
| December 20, 2007 |
Altor BioScience Advances Clinical Trial for Targeted Cancer Therapeutic, ALT-801 |
| July 25, 2006 |
Altor BioScience Awarded Phase II SBIR Grant for Anti-Cancer Antibody Manufacture in Transgenic Plants |
| March 13, 2006 |
Altor BioScience Introduces STAR(TM) Multimer Reagents to Measure Disease-Specific Antigen Presentation |
| July 21, 2005 |
Altor BioScience Awarded SBIR Grant for Manufacturing Therapeutic Antibodies in Transgenic Plants |
| January 19, 2005 |
Altor BioScience Establishes Collaboration with Leading MGH Investigator to Develop TCR-based Agents to Detect and Treat HIV and HCV Infection |
| September 20, 2004 |
Altor Bioscience Receives Phase II SBIR Grant for Next-Generation Cancer Therapeutics |
| March 29, 2004 |
Altor BioScience Reports Advancements in its Soluble T-cell Receptor-Based Technology Programs |
| November 11, 2003 |
Altor Bioscience Reports Pre-Clinical Results Supporting Utility of Soluble T-Cell Receptor Fusions for Cancer Immunotherapy |
| September 26, 2003 |
Altor Bioscience Awarded NIH Grant to Expand Screening Program to Identify Orally Available Drugs to Treat Multiple Sclerosis |
| June 1, 2003 |
Altor Bioscience Receives SBIR Grant from NIAID for Development of Anti-Viral TCR Therapeutics |
| March 18, 2003 |
Altor Bioscience Issued New U.S. Patent for Innovative T-cell Receptor Technology |
Other Publicity:
- Miramar firm showcases South Florida's life-science industry. Sun Sentinel, June 3, 2001. (Link)
- Altor BioScience Corporation – Company Profile by Hing Wong. Biomarkers Med. (2010) 4(4), 499–504 (ISSN 1752-0363) (10.2217/BMM.10.69 © 2010 Future Medicine Ltd. (Link)
- NCI SBIR Grants $11 .5M in Bridge Awards BioWorld Today, December 21, 2009 (Link)
- Emerging Drug Developer: Altor BioScience Carroll, John. Fierce Biotech May 4, 2009. (Link)
- Altor pinpoints treatments to the target Maurer, Allan. TechJournal South March-April 2009 (Link)
- Altor BioScience Corp. Kling, Jim Start-Up November 1, 2008 (Link)
- Altor Bioscience Banks $10M To Propel Pipeline. Gormley, Brian. VentureWire Aug. 27, 2008 (Link)
- Altor Bioscience Seeks $15M Series C For Cancer Therapy. Gormley, Brian. VentureWire April 25, 2007 (Link)
- Company Hits Iceberg Solution. South Florida CEO, November 2006 (Link)
- Altor Moving to Clinic With T-Cell Receptor-Based Drug. Boggs, Jennifer. BioWorld Today, August 10, 2006 (Link)
- New drug leaves diseased cells nowhere to hide. Coghlan, Andy, New Scientist, April 21, 2002.
Also see: Altor featured on NCI's website as a success story (Link)
Back
© Altor BioScience Corporation, 2011
